Cargando…

Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations

Amoxicillin-clavulanic acid (AMC) belongs to the WHO Essential Medicines List for children, but for optimal antimicrobial effectiveness, reconstituted dry powder suspensions need to be stored in a refrigerated environment. Many patients in low- and middle-income countries who are sold AMC suspension...

Descripción completa

Detalles Bibliográficos
Autores principales: Mack, Ines, Sharland, Mike, Brussee, Janneke M., Rehm, Sophia, Rentsch, Katharina, Bielicki, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927114/
https://www.ncbi.nlm.nih.gov/pubmed/33672363
http://dx.doi.org/10.3390/antibiotics10020225
_version_ 1783659618702983168
author Mack, Ines
Sharland, Mike
Brussee, Janneke M.
Rehm, Sophia
Rentsch, Katharina
Bielicki, Julia
author_facet Mack, Ines
Sharland, Mike
Brussee, Janneke M.
Rehm, Sophia
Rentsch, Katharina
Bielicki, Julia
author_sort Mack, Ines
collection PubMed
description Amoxicillin-clavulanic acid (AMC) belongs to the WHO Essential Medicines List for children, but for optimal antimicrobial effectiveness, reconstituted dry powder suspensions need to be stored in a refrigerated environment. Many patients in low- and middle-income countries who are sold AMC suspensions would be expected not to keep to the specified storage conditions. We aimed to assess the stability of both ingredients in liquid formulations and dispersible tablets, combined with nationally representative data on access to appropriate storage. Degradation of amoxicillin (AMX) and clavulanic-acid (CLA) was measured in suspensions and dispersible tablets commercially available in Switzerland at different ambient temperatures (8 °C vs. 28 °C over 7 days, and 23 °C vs. 28 °C over 24 h, respectively). Data on access to refrigeration and electricity were assessed from the USAID-funded Demographic and Health Survey program. In suspensions, CLA degraded to a maximum of 12.9% (95% CI −55.7%, +29.9%) at 8°C and 72.3% (95% CI −82.8%, −61.8%) at a 28 °C ambient temperature during an observation period of 7 days. Dispersible tablets were observed during 24 h and CLA degraded to 15.4% (95% CI −51.9%, +21.2%) at 23 °C and 21.7% (−28.2%, −15.1%) at a 28 °C ambient temperature. There is relevant degradation of CLA in suspensions during a 7-day course. To overcome the stability challenges for all active components, durable child-appropriate formulations are needed. Until then, prescribers of AMC suspensions or pharmacists who sell the drug need to create awareness for the importance of proper storage conditions regarding effectiveness of both antibiotics and this recommendation should be reflected in the WHO Essential Medicines List for children.
format Online
Article
Text
id pubmed-7927114
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79271142021-03-04 Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations Mack, Ines Sharland, Mike Brussee, Janneke M. Rehm, Sophia Rentsch, Katharina Bielicki, Julia Antibiotics (Basel) Article Amoxicillin-clavulanic acid (AMC) belongs to the WHO Essential Medicines List for children, but for optimal antimicrobial effectiveness, reconstituted dry powder suspensions need to be stored in a refrigerated environment. Many patients in low- and middle-income countries who are sold AMC suspensions would be expected not to keep to the specified storage conditions. We aimed to assess the stability of both ingredients in liquid formulations and dispersible tablets, combined with nationally representative data on access to appropriate storage. Degradation of amoxicillin (AMX) and clavulanic-acid (CLA) was measured in suspensions and dispersible tablets commercially available in Switzerland at different ambient temperatures (8 °C vs. 28 °C over 7 days, and 23 °C vs. 28 °C over 24 h, respectively). Data on access to refrigeration and electricity were assessed from the USAID-funded Demographic and Health Survey program. In suspensions, CLA degraded to a maximum of 12.9% (95% CI −55.7%, +29.9%) at 8°C and 72.3% (95% CI −82.8%, −61.8%) at a 28 °C ambient temperature during an observation period of 7 days. Dispersible tablets were observed during 24 h and CLA degraded to 15.4% (95% CI −51.9%, +21.2%) at 23 °C and 21.7% (−28.2%, −15.1%) at a 28 °C ambient temperature. There is relevant degradation of CLA in suspensions during a 7-day course. To overcome the stability challenges for all active components, durable child-appropriate formulations are needed. Until then, prescribers of AMC suspensions or pharmacists who sell the drug need to create awareness for the importance of proper storage conditions regarding effectiveness of both antibiotics and this recommendation should be reflected in the WHO Essential Medicines List for children. MDPI 2021-02-23 /pmc/articles/PMC7927114/ /pubmed/33672363 http://dx.doi.org/10.3390/antibiotics10020225 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mack, Ines
Sharland, Mike
Brussee, Janneke M.
Rehm, Sophia
Rentsch, Katharina
Bielicki, Julia
Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations
title Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations
title_full Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations
title_fullStr Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations
title_full_unstemmed Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations
title_short Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations
title_sort insufficient stability of clavulanic acid in widely used child-appropriate formulations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927114/
https://www.ncbi.nlm.nih.gov/pubmed/33672363
http://dx.doi.org/10.3390/antibiotics10020225
work_keys_str_mv AT mackines insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations
AT sharlandmike insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations
AT brusseejannekem insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations
AT rehmsophia insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations
AT rentschkatharina insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations
AT bielickijulia insufficientstabilityofclavulanicacidinwidelyusedchildappropriateformulations